Screening, diagnosis, treatment, and follow up of hepatitis C virus related liver disease. National consensus guideline in Hungary from 15 October 2016
Treatment of hepatitis C is based on a national consensus guideline updated six-monthly according to local availability and affordability of approved therapies through a transparent allocation system in Hungary. This updated guideline incorporates some special new aspects, including recommendations for screening, diagnostics, use and allocation of novel direct acting antiviral agents. Indication of therapy in patients with no contraindication is based on demonstration of viral replication with consequent inflammation and/or fibrosis in the liver. Non-invasive methods (elastographies and biochemical methods) are preferred for liver fibrosis staging. The budget allocated for these patients is limited. Therefore, expensive novel direct acting antiviral combinations as first line treatment are reimbursed only, if the freely available, but less effective and more toxic pegylated interferon plus ribavirin dual therapy deemed to prone high chance of adverse events and/or low chance of cure. Priority is given to those with urgent need based on a pre-defined scoring system reflecting mainly the stage of the liver disease, but considering also additional factors, i.e., hepatic decompensation, other complications, activity and progression of liver disease, risk of transmission and other special issues. Approved treatments are restricted to the most cost-effective combinations based on the cost per sustained virological response value in different patient categories with consensus amongst treating physicians, the National Health Insurance Fund and patient's organizations. Interferon-free treatments and shorter therapy durations are preferred. Orv. Hetil., 2017, 158(Suppl. 1), 3-22.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:158 |
|---|---|
| Enthalten in: |
Orvosi hetilap - 158(2017), Suppl 1 vom: 01. Feb., Seite 3-22 |
| Sprache: |
Ungarisch |
|---|
| Weiterer Titel: |
A hepatitis C-vírus-fertőzés szűrése, diagnosztikája, antivirális terápiája, kezelés utáni gondozása. Magyar konszenzusajánlás. Érvényes: 2016. október 15-től |
|---|
| Beteiligte Personen: |
Hunyady, Béla [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 02.07.2019 Date Revised 02.07.2019 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1556/650.2017.30688 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM269133496 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM269133496 | ||
| 003 | DE-627 | ||
| 005 | 20231224223958.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2017 xx |||||o 00| ||hun c | ||
| 024 | 7 | |a 10.1556/650.2017.30688 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0897.xml |
| 035 | |a (DE-627)NLM269133496 | ||
| 035 | |a (NLM)28218867 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a hun | ||
| 100 | 1 | |a Hunyady, Béla |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Screening, diagnosis, treatment, and follow up of hepatitis C virus related liver disease. National consensus guideline in Hungary from 15 October 2016 |
| 246 | 3 | 3 | |a A hepatitis C-vírus-fertőzés szűrése, diagnosztikája, antivirális terápiája, kezelés utáni gondozása. Magyar konszenzusajánlás. Érvényes: 2016. október 15-től |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.07.2019 | ||
| 500 | |a Date Revised 02.07.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Treatment of hepatitis C is based on a national consensus guideline updated six-monthly according to local availability and affordability of approved therapies through a transparent allocation system in Hungary. This updated guideline incorporates some special new aspects, including recommendations for screening, diagnostics, use and allocation of novel direct acting antiviral agents. Indication of therapy in patients with no contraindication is based on demonstration of viral replication with consequent inflammation and/or fibrosis in the liver. Non-invasive methods (elastographies and biochemical methods) are preferred for liver fibrosis staging. The budget allocated for these patients is limited. Therefore, expensive novel direct acting antiviral combinations as first line treatment are reimbursed only, if the freely available, but less effective and more toxic pegylated interferon plus ribavirin dual therapy deemed to prone high chance of adverse events and/or low chance of cure. Priority is given to those with urgent need based on a pre-defined scoring system reflecting mainly the stage of the liver disease, but considering also additional factors, i.e., hepatic decompensation, other complications, activity and progression of liver disease, risk of transmission and other special issues. Approved treatments are restricted to the most cost-effective combinations based on the cost per sustained virological response value in different patient categories with consensus amongst treating physicians, the National Health Insurance Fund and patient's organizations. Interferon-free treatments and shorter therapy durations are preferred. Orv. Hetil., 2017, 158(Suppl. 1), 3-22 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a direct acting antiviral drug | |
| 650 | 4 | |a direkt ható antivirális szer | |
| 650 | 4 | |a genotype | |
| 650 | 4 | |a genotípus | |
| 650 | 4 | |a hepatitis C virus | |
| 650 | 4 | |a hepatitis C-vírus | |
| 650 | 4 | |a hepatocellular carcinoma | |
| 650 | 4 | |a interferon | |
| 650 | 4 | |a liver cirrhosis | |
| 650 | 4 | |a májrák | |
| 650 | 4 | |a májzsugor | |
| 650 | 4 | |a polimerázgátló | |
| 650 | 4 | |a polymerase inhibitor | |
| 650 | 4 | |a protease inhibitor | |
| 650 | 4 | |a proteázgátló | |
| 650 | 4 | |a replication complex inhibitor | |
| 650 | 4 | |a replikációskomplex-gátló | |
| 650 | 4 | |a viral hepatitis | |
| 650 | 4 | |a vírushepatitis | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Protease Inhibitors |2 NLM | |
| 700 | 1 | |a Gerlei, Zsuzsanna |e verfasserin |4 aut | |
| 700 | 1 | |a Gervain, Judit |e verfasserin |4 aut | |
| 700 | 1 | |a Horváth, Gábor |e verfasserin |4 aut | |
| 700 | 1 | |a Lengyel, Gabriella |e verfasserin |4 aut | |
| 700 | 1 | |a Pár, Alajos |e verfasserin |4 aut | |
| 700 | 1 | |a Péter, Zoltán |e verfasserin |4 aut | |
| 700 | 1 | |a Rókusz, László |e verfasserin |4 aut | |
| 700 | 1 | |a Schneider, Ferenc |e verfasserin |4 aut | |
| 700 | 1 | |a Szalay, Ferenc |e verfasserin |4 aut | |
| 700 | 1 | |a Tornai, István |e verfasserin |4 aut | |
| 700 | 1 | |a Werling, Klára |e verfasserin |4 aut | |
| 700 | 1 | |a Makara, Mihály |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Orvosi hetilap |d 1949 |g 158(2017), Suppl 1 vom: 01. Feb., Seite 3-22 |w (DE-627)NLM000021601 |x 1788-6120 |7 nnns |
| 773 | 1 | 8 | |g volume:158 |g year:2017 |g number:Suppl 1 |g day:01 |g month:02 |g pages:3-22 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1556/650.2017.30688 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 158 |j 2017 |e Suppl 1 |b 01 |c 02 |h 3-22 | ||